Insights Into Metastatic Colorectal Cancer (mCRC) (Arizona)

Expert analysis on treatment approaches, shared decision-making, and emerging options for refractory mCRC from academic and community oncology practices in Arizona.

Tempe, AZ — October 4, 2025
Purchase Report

FACULTY CHAIR

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Scottsdale, AZ, USA

Example Report

Start discovering the insights

View Report

MORE INFORMATION

  • Casa Grande, AZ
  • Chandler, AZ
  • Gilbert, AZ
  • Glendale, AZ
  • Mesa, AZ
  • Phoenix, AZ
  • Scottsdale, AZ

REPORT SNAPSHOT

  • Explore key differences in physicians’ approaches between academic and community-based settings
  • Understand how clinical factors and patient characteristics influence choices for third- and fourth-line treatments in refractory mCRC
  • Gauage physician awareness and adoption of novel options like fruquintinib, and gain insights into shared decision-making and practice drivers

GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT

  • Data collection was conducted through the utilization of an audience response system and facilitated moderated discussion
  • The experts included 15 community oncologists from Arizona

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.